Ionis Pharmaceuticals IONS Equity Securities Fv Ni Accumulated Gross Unrealized Gain
Equity Securities Fv Ni Accumulated Gross Unrealized Gain at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:EquitySecuritiesFvNiAccumulatedGrossUnrealizedGain.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized gain.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized gain?
- Ionis Pharmaceuticals (IONS) reported equity securities fv ni accumulated gross unrealized gain of $65.67M in Q1 2026.
- How has Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized gain changed year-over-year?
- Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized gain increased by 162.2% year-over-year, from $25.04M to $65.67M.
- What is the long-term trend for Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized gain?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's equity securities fv ni accumulated gross unrealized gain has grown at a 22.9% compound annual growth rate (CAGR), from $23.85M to $54.43M.
- What does equity securities fv ni accumulated gross unrealized gain mean?
- The total paper profit on equity investments that directly affects the company's net income.
- How do you interpret equity securities fv ni accumulated gross unrealized gain?
- An increase indicates that the company's strategic equity investments are appreciating in value, boosting reported net income.
- How does equity securities fv ni accumulated gross unrealized gain compare across companies?
- Highly variable across biotech companies depending on their strategic investment and partnership activity.